Good afternoon and welcome to the Hologic's first quarter fiscal 2025 earnings conference call. My name is Lisa and I'm your operator for today's call. Today's conference is being recorded. All lines ...

Leerink downgraded Hologic (HOLX) to Market Perform from Outperform with a price target of $75, down from $80, following the fiscal Q1 report.

Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

The company guided Q2 2025 revenues to be between $995 million and $1.005 billion, with non-GAAP EPS expected in the range of $1 to $1.03. Full-year revenue guidance was revised to $4.05 billion to $4 ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Hologic (HOLX – Research Report) yesterday. The company’s shares closed yesterday at ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

Hologic Inc (NASDAQ:HOLX). reported its financial results for the first quarter of fiscal year 2025, showing a slight beat in earnings per share (EPS) but falling short on revenue expectations. The ...

Explore advancements in women's health through AI, equity, and policy with Mia Keeys of Hologic on I Don’t Care.

The stock's rise snapped a three-day losing streak.

Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company ...

Medical technology company Hologic (NASDAQ:HOLX) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat ...

MARLBOROUGH, Mass. (AP) — MARLBOROUGH, Mass. (AP) — Hologic Inc. (HOLX) on Wednesday reported fiscal first-quarter profit of $201 million. On a per-share basis, the Marlborough, Massachusetts-based ...